Biomea Fusion, Inc. earnings releases BMEA

Annual Quarterly

Biomea Fusion, Inc. last reported quarterly results on May 11, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): diluted EPS of -$0.17. It usually reports 35–41 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 11, 2026 41 days after quarter end	Q1 FY2026 ended Mar 31, 2026	—	-12 +57.6%	-0.17 +78.8%
Nov 4, 2025 35 days after quarter end	Q3 FY2025 ended Sep 30, 2025	—	-16 +50.0%	-0.27 +70.3%
Aug 5, 2025 36 days after quarter end	Q2 FY2025 ended Jun 30, 2025	—	-21 +44.4%	-0.51 +50.5%
May 5, 2025 35 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-29 +25.1%	-0.80 +26.6%
Oct 29, 2024 29 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-33 -15.3%	-0.91 -13.7%
Jul 31, 2024 31 days after quarter end	— ended Jun 30, 2024	—	—	—
Apr 1, 2024 1 days after quarter end	— ended Mar 31, 2024	—	—	—
Oct 30, 2023 30 days after quarter end	— ended Sep 30, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BMEA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: San Carlos, CA
SEC filer status: , Emerging growth company
SEC CIK: 1840439

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.